Skye Bioscience (NASDAQ:SKYE) Releases Earnings Results, Beats Expectations By $0.06 EPS

Posted by Lauren Steadman on Mar 21st, 2025

Skye Bioscience (NASDAQ:SKYE – Get Free Report) posted its earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06, Zacks reports. During the same period in the previous year, the business posted ($0.36) EPS.

Skye Bioscience Stock Down 5.5 %

Shares of SKYE stock opened at $1.89 on Friday. The business’s fifty day simple moving average is $2.69 and its 200-day simple moving average is $2.84. Skye Bioscience has a 12-month low of $1.83 and a 12-month high of $17.65.

Wall Street Analysts Forecast Growth

Separately, William Blair initiated coverage on Skye Bioscience in a report on Friday, February 28th. They set an “outperform” rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $18.67.

Check Out Our Latest Analysis on SKYE

About Skye Bioscience

(Get Free Report)

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.